Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,861 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,861 Papers indexed
1,440 Papers AI scored
39,861 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-10-30 09:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39861 results
B
Distribution of ABO/Rh Blood Types Across Childhood Leukemia Subtypes: A Retrospective Cohort Study of 540 Pediatric Patients.
PMID 41618027 Published: 2026-01-30 Ingested: 2026-08-02 12:06 AM European journal of haematology
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 16.0; sample size: 80.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 16.0; sample size: 80.0; recency: 100.0; abstract quality: 100.0.

B
HSCT Conditioning for Children: The Art in the Science.
PMID 41508862 Published: 2026-01-09 Ingested: 2026-08-02 12:06 AM Pediatric hematology and oncology
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 81.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
VEGF mRNA expression as a powerful independent predictor for recurrence in ameloblastoma: Integrating molecular profiling with surgical outcome analysis.
PMID 41482063 Published: 2025-12-31 Ingested: 2026-08-02 12:05 AM Journal of stomatology, oral and maxillofacial surgery
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 21.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?
PMID 41348006 Published: 2025-12-05 Ingested: 2026-08-02 12:05 AM Hematology. American Society of Hematology. Education Program
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 81.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
Fertility preservation in women with sarcoma: A real-world experience.
PMID 41257524 Published: 2025-11-19 Ingested: 2026-08-02 12:05 AM International journal of cancer
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 66.0; sample size: 50.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 21.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 66.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
Malignant Rhabdoid Tumors of the Liver Are Associated With Inferior Outcomes Compared to Other Extracranial Rhabdoid Tumors.
PMID 40974093 Published: 2025-09-19 Ingested: 2026-08-02 12:05 AM Pediatric blood & cancer
AI -
Standard 70.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 66.0; sample size: 50.0; recency: 100.0; abstract quality: 85.0.

Previous
Page 659 of 3322
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic